Rachel Teitelbaum of Hervana, Ltd. in Israel will develop and test a vaginal formulation that secretes an agent which inhibits sperm motility thus interfering with fertilization. It is hoped that this non-hormonal contraceptive will need only infrequent administration to maintain its effectiveness.
Grant ID
OPP1043778
Show on Hub
Off
Show on Spoke
Off
Follow-on Funding
Off
Lead Funding Organization
Initiatives
Principal Investigator
Award Manager
Individual Funder Information
Funding Organization
Funding Amount (in original currency)
996071.00
Funding Currency
USD
Funding Amount (in USD)
996071.00
Project Type
Project Primary Sector
Project Subsector
Funding Date Range
-
Funding Total (In US dollars)
996071.00
Initial Grant
Co-Funded
False